Literature DB >> 8006335

Long-term treatment of Nelson's syndrome by octreotide: a case report.

L Petrini1, M Gasperi, R Pilosu, A Marcello, E Martino.   

Abstract

Medical management of Nelson's syndrome by drugs such as bromocriptine, sodium and magnesium valproate has provided disappointing or, at least, controversial results. We report here on the results of long-term (2 yr) treatment with the somatostatin analogue octreotide (300 micrograms daily sc) in one patient affected by Nelson's syndrome occurring after bilateral adrenalectomy for Cushing's syndrome. During treatment, skin hyperpigmentation and serum ACTH levels decreased dramatically and a slight (about 10%) reduction in tumor size, as assessed by computerized tomography, was also observed. These results suggest that octreotide may be useful for the medical management of Nelson's syndrome.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8006335     DOI: 10.1007/BF03347703

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  21 in total

1.  ACTH-producing pituitary tumors following adrenalectomy for Cushing's syndrome.

Authors:  D H NELSON; J W MEAKIN; G W THORN
Journal:  Ann Intern Med       Date:  1960-03       Impact factor: 25.391

2.  Inhibition by somatostatin of ACTH secretion in Nelson's syndrome.

Authors:  J B Tyrrell; M Lorenzi; J E Gerich; P H Forsham
Journal:  J Clin Endocrinol Metab       Date:  1975-06       Impact factor: 5.958

3.  Treatment of pituitary macroadenomas secreting PRL, HGH or ACTH with long-acting bromocriptine.

Authors:  I Halperin; M D Rodriguez; C Cardenal; R Casamitjana; M J Martinez Osaba; V Lienas; E Vilardell
Journal:  J Endocrinol Invest       Date:  1987-06       Impact factor: 4.256

4.  Size reduction of an ACTH-secreting pituitary macroadenoma in Nelson's syndrome by sodium valproate: effect of withdrawal and re-institution of treatment.

Authors:  P Loli; M E Berselli; F Vignati; C De Grandi; M Tagliaferri
Journal:  Acta Endocrinol (Copenh)       Date:  1988-11

5.  Observations on the pathophysiology of Nelson's syndrome: a report of three cases.

Authors:  M Buchfelder; R Fahlbusch; P Thierauf; O A Müller
Journal:  Neurosurgery       Date:  1990-12       Impact factor: 4.654

6.  Long-term treatment of Nelson's syndrome with sodium valproate.

Authors:  W Kelly; J E Adams; I Laing; D Longson; D Davies
Journal:  Clin Endocrinol (Oxf)       Date:  1988-02       Impact factor: 3.478

7.  The effect of the long-acting somatostatin analogue SMS 201-995 on ACTH secretion in Nelson's syndrome and Cushing's disease.

Authors:  S W Lamberts; P Uitterlinden; J M Klijn
Journal:  Acta Endocrinol (Copenh)       Date:  1989-06

Review 8.  The role of octreotide (Sandostatin) in non-growth hormone-, non-thyroid-stimulating hormone-, and non-prolactin-secreting adenomas.

Authors:  A Warnet
Journal:  Metabolism       Date:  1992-09       Impact factor: 8.694

Review 9.  Potential indications for octreotide in endocrinology.

Authors:  K von Werder; G Faglia
Journal:  Metabolism       Date:  1992-09       Impact factor: 8.694

10.  ACTH secreting pituitary tumours.

Authors:  J D Nabarro
Journal:  J R Coll Physicians Lond       Date:  1977-07
View more
  6 in total

Review 1.  The role of somatostatin analogs in Cushing's disease.

Authors:  Joost van der Hoek; Steven W J Lamberts; Leo J Hofland
Journal:  Pituitary       Date:  2004       Impact factor: 4.107

Review 2.  Cushing's disease.

Authors:  Martina De Martin; Francesca Pecori Giraldi; Francesco Cavagnini
Journal:  Pituitary       Date:  2006       Impact factor: 4.107

3.  Treatment of Cushing disease: overview and recent findings.

Authors:  Tatiana Mancini; Teresa Porcelli; Andrea Giustina
Journal:  Ther Clin Risk Manag       Date:  2010-10-21       Impact factor: 2.423

Review 4.  Pituitary disorders. Drug treatment options.

Authors:  J J Orrego; A L Barkan
Journal:  Drugs       Date:  2000-01       Impact factor: 9.546

Review 5.  Somatostatin and dopamine receptors as targets for medical treatment of Cushing's Syndrome.

Authors:  C de Bruin; R A Feelders; S W J Lamberts; L J Hofland
Journal:  Rev Endocr Metab Disord       Date:  2008-07-19       Impact factor: 6.514

6.  Corticotroph tumor progression after bilateral adrenalectomy (Nelson's syndrome): systematic review and expert consensus recommendations.

Authors:  Martin Reincke; Adriana Albani; Guillaume Assie; Irina Bancos; Thierry Brue; Michael Buchfelder; Olivier Chabre; Filippo Ceccato; Andrea Daniele; Mario Detomas; Guido Di Dalmazi; Atanaska Elenkova; James Findling; Ashley B Grossman; Celso E Gomez-Sanchez; Anthony P Heaney; Juergen Honegger; Niki Karavitaki; Andre Lacroix; Edward R Laws; Marco Losa; Masanori Murakami; John Newell-Price; Francesca Pecori Giraldi; Luis G Pérez-Rivas; Rosario Pivonello; William E Rainey; Silviu Sbiera; Jochen Schopohl; Constantine A Stratakis; Marily Theodoropoulou; Elisabeth F C van Rossum; Elena Valassi; Sabina Zacharieva; German Rubinstein; Katrin Ritzel
Journal:  Eur J Endocrinol       Date:  2021-03       Impact factor: 6.664

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.